novartis-investor-presentation-jpm-2026-growth-story.pdf

《novartis-investor-presentation-jpm-2026-growth-story.pdf》由会员分享，可在线阅读，更多相关《novartis-investor-presentation-jpm-2026-growth-story.pdf（31页珍藏版）》请在三个皮匠报告上搜索。

1、Novartis growth storyVas Narasimhan,CEOJ.P.Morgan Healthcare ConferenceJanuary 12,2026DisclaimerNovartis growth story|January 12,20262Cautionary Statement Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the United States Private Securi

2、ties Litigation Reform Act of 1995,that can generally be identified by words such as“anticipate,”“can,”“will,”“continue,”“ongoing,”“growth,”“launch,”“expect,”“expand,”“deliver,”“accelerate,”“guidance,”“outlook,”“priority,”“potential,”“momentum,”“commitment,”“on track,”or similar expressions,or by ex

3、press or implied discussions regarding potential new products,potential new indications for existing products,potential product launches,or regarding potential future revenues from any such products;or regarding results of ongoing clinical trials;or regarding potential future,pending or announced tr

4、ansactions;regarding potential future sales or earnings;or by discussions of strategy,plans,expectations or intentions,including discussions regarding our continued investment into new R&D capabilities and manufacturing;or regarding our capital structure.Such forward-looking statements are based on

5、the current beliefs and expectations of management regarding future events and are subject to significant known and unknown risks and uncertainties.Should one or more of these risks or uncertainties materialize,or should underlying assumptions prove incorrect,actual results may vary materially from

6、those set forth in the forward-looking statements.You should not place undue reliance on these statements.There can be no guarantee that the investigational or approved products described in this presentation will be submitted or approved for sale or for any additional indications or labeling in any